TUG1 and glioma: Systemically administered TUG1-targeted ASO (asTUG1)/uPIC appreciably reduced the expression of TUG1 (>90%) in the glioma tissue compared with a Luc-targeted ASO(asLuc)/uPIC control (Fig. 5b).